Prescribing Patterns for Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Chronic Kidney Disease: Retrospective Analysis at an Academic Family Medicine Center
Year: 2026
Type: dissertation
Study design: Observational Study
Abstract: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated significant renal and cardiovascular benefits in patients with chronic kidney disease (CKD), yet their prescribing rates remain low, particularly in patients without diabetes. This retrospective, single-center study analyzed 358 non-dialysis CKD patients to identify factors associated with SGLT2i use. Of these, 49% received an SGLT2i prescription, with prescribing more common in those with diabetes, heart failure, or existing cardiovascular disease. Multivariate analysis revealed that heart failure, renin-angiotensin system inhibitor use, insulin, and GLP-1 agonists were independently associated with increased SGLT2i prescribing, while prior stroke was linked to lower use. These findings suggest that SGLT2i are primarily prescribed for their cardiovascular and metabolic benefits rather than their renal-protective effects. Targeted efforts to enhance provider awareness of CKD-specific guideline recommendations may help bridge this gap and optimize outcomes for patients with CKD.
DOI: 10.17615/4c3a-z128
Author: McCue, Alina
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7161406650
Cites:
Cited by:
Related to: